Lantheus Holdings, Inc. LNTH

What this company does

Lantheus Holdings produces and markets its products throughout the United States, selling primarily to hospitals, independent imaging centers and government facilities. The company is headquartered in Massachusetts, with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom. As of December 31, 2025, it had 1,193 employees, of whom 1,056 were located in the United States and 137 internationally. For the years ended December 31, 2025, 2024 and 2023, it invested $177.3 million, $168.1 million and $77.7 million, respectively, in research and development. It classifies its products into three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its Radiopharmaceutical Oncology category consists of PYLARIFY, an F-18-labeled PET imaging agent targeting PSMA used with PET/computed tomography, approved by the FDA in May 2021 and commercially launched in the United States in June 2021. Its Precision Diagnostics category includes DEFINITY, an injectable ultrasound enhancing agent with perflutren-containing lipid microspheres used in echocardiography exams, and Neuraceq, an F-18 labeled PET imaging agent that binds selectively to beta-amyloid plaques in the brain and was approved by the FDA in 2014. Founded in 1956 as New England Nuclear Corporation, its medical imaging diagnostic business was purchased by E.I. du Pont de Nemours and Company in 1981 and was subsequently acquired by Bristol Myers Squibb as part of its acquisition of DuPont Pharmaceuticals in 2001.

Written from the business description in LANTHEUS HOLDINGS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.